Abstract
Amphetamine extended-release oral suspension (Adzenys ER, Neos Therapeutics): An orange-flavored, sorbitol-sweetened liquid formulation has been added to the product line. The suspension contains a 3:1 ratio of d-amphetamine to l-amphetamine and is not to be substituted milligram for milligram with other amphetamine products. The drug is a Schedule II controlled substance and subject to FDA Medication Guide requirements. Bevacizumab-awwb solution for i.v. infusion (Mvasi, Amgen): The biosimilar to bevacizumab, a vascular endothelial growth factor inhibitor, is indicated for use in combination with fluorouracil in the treatment of metastatic colorectal cancer; in combination with chemotherapy regimens containing fluoropyrimidine and irinotecan or fluoropyrimidine and oxaliplatin, for the treatment of metastatic colorectal cancer that has progressed after first-line bevacizumab therapy; in combination with carboplatin and paclitaxel, for the first-line treatment of unresectable, locally advanced nonsquamous non–small cell lung cancer that has recurred or metastasized; in combination with interferon alfa, for the treatment of metastatic renal cell carcinoma; in combination with regimens containing paclitaxel and cisplatin or paclitaxel and topotecan, in the treatment of cervical cancer that persists or has recurred or metastasized; and for treatment of progressive glioblastoma in adults who received prior therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
